loading
Precedente Chiudi:
$4.45
Aprire:
$4.49
Volume 24 ore:
433.38K
Relative Volume:
0.40
Capitalizzazione di mercato:
$295.17M
Reddito:
-
Utile/perdita netta:
$-27.03M
Rapporto P/E:
-7.7321
EPS:
-0.56
Flusso di cassa netto:
$-23.97M
1 W Prestazione:
+3.84%
1M Prestazione:
+9.34%
6M Prestazione:
-20.40%
1 anno Prestazione:
+100.46%
Intervallo 1D:
Value
$4.30
$4.53
Intervallo di 1 settimana:
Value
$4.095
$4.53
Portata 52W:
Value
$2.13
$10.00

Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile

Name
Nome
Corvus Pharmaceuticals Inc
Name
Telefono
(650) 900-4520
Name
Indirizzo
863 MITTEN ROAD, BURLINGAME, CA
Name
Dipendente
31
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-25
Name
Ultimi documenti SEC
Name
CRVS's Discussions on Twitter

Confronta CRVS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CRVS
Corvus Pharmaceuticals Inc
4.33 321.57M 0 -27.03M -23.97M -0.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-02 Iniziato H.C. Wainwright Buy
2023-08-18 Iniziato Oppenheimer Outperform
2021-12-01 Ripresa Jefferies Buy
2021-05-27 Iniziato Cantor Fitzgerald Overweight
2021-02-10 Downgrade Mizuho Buy → Neutral
2019-09-12 Iniziato Mizuho Buy
2019-05-29 Iniziato ROTH Capital Buy
2017-08-24 Aggiornamento Credit Suisse Underperform → Neutral
2017-05-01 Downgrade Credit Suisse Neutral → Underperform
2016-04-18 Iniziato Credit Suisse Outperform
2016-04-18 Iniziato Guggenheim Buy
Mostra tutto

Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie

pulisher
Jul 22, 2025

Corvus Pharmaceuticals Inc. Stock Analysis and ForecastUnstoppable investment returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Corvus Pharmaceuticals Inc. stock priceUnmatched market performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Corvus Pharmaceuticals Inc. a good long term investmentUnstoppable trading performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

What analysts say about Corvus Pharmaceuticals Inc. stockExplosive trading growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 15, 2025

Why Corvus Pharmaceuticals Inc. stock attracts strong analyst attentionReal Time Alert Service - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Corvus Pharmaceuticals Inc. stock price move sharplyDouble Your Capital Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Corvus Pharmaceuticals Inc. stock performs during market volatilityDaily Breakout Picks - Newser

Jul 15, 2025
pulisher
Jul 08, 2025

Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says - MarketScreener

Jul 08, 2025
pulisher
Jul 03, 2025

Corvus Pharmaceuticals’ Promising Study on Soquelitinib for Atopic Dermatitis - TipRanks

Jul 03, 2025
pulisher
Jul 02, 2025

Corvus Pharmaceuticals: Insider Confidence and Clinical Catalysts Fueling Growth - AInvest

Jul 02, 2025
pulisher
Jul 01, 2025

OrbiMed Advisors sells Corvus Pharma (CRVS) shares worth $4.89 million By Investing.com - Investing.com Canada

Jul 01, 2025
pulisher
Jun 30, 2025

Corvus Pharmaceuticals, Inc.(NasdaqGM: CRVS) added to Russell 3000 Index - MarketScreener

Jun 30, 2025
pulisher
Jun 25, 2025

Corvus Pharmaceuticals (CRVS) Gains China Approval for Soquelitinib Trial | CRVS Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Major Breakthrough: Corvus Expands Atopic Dermatitis Drug Development into Chinese Market with New Trial Approval - Stock Titan

Jun 25, 2025
pulisher
Jun 18, 2025

Financial Metrics Exploration: Understanding Corvus Pharmaceuticals Inc (CRVS) Through Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Corvus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 11, 2025

Breakthrough Systemic Sclerosis Treatment Shows Promise in Top EULAR Study | CRVS Stock News - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - TradingView

Jun 11, 2025
pulisher
Jun 10, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jun 10, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Reports 'Clinically Meaningful' Itch Reduction in Latest Phase 1 Atopic Dermatitis Drug Trial Results - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus reports promising interim data on atopic dermatitis drug - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals (CRVS) Reports Promising Results for Atopic Dermatitis Treatment | CRVS Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data From Cohort 3 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Corvus Pharmaceuticals Announces Full Data from Cohort 3 - GlobeNewswire

Jun 04, 2025
pulisher
May 28, 2025

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 28, 2025
pulisher
May 28, 2025

Exclusive: Corvus Pharmaceuticals Reveals Latest Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan

May 28, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN

May 20, 2025
pulisher
May 20, 2025

CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Mizuho cuts Corvus Pharmaceuticals target to $11, keeps rating - Investing.com

May 20, 2025
pulisher
May 13, 2025

Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World

May 13, 2025
pulisher
May 12, 2025

Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus

May 12, 2025

Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Capitalizzazione:     |  Volume (24 ore):